J&J Beats $258M Risperdal Verdict In Split La. High Court

Law360, New York (January 28, 2014, 8:11 PM EST) -- A split Louisiana Supreme Court on Tuesday nixed a $258 million jury award against Johnson & Johnson unit Janssen Pharmaceuticals Inc. over its marketing of the antipsychotic drug Risperdal, finding that the state failed to prove the companies defrauded Louisiana’s Medicaid program.

In a significant win for J&J, the state high court ruled 4-3 to reverse an August 2012 appeals court decision that preserved a $258 million jury verdict against Janssen secured by state Attorney General James D. “Buddy” Caldwell. The nearly decadelong dispute stems from...
To view the full article, register now.